INVA   $19.1  0.10% Market Open

Innoviva Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bullish recovery. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-08-06 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.

2023-08-05 Trend pattern changed from восходящий треугольник to сужающийся канал.

2023-08-05 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-04 Trend pattern changed from симметричный треугольник to восходящий треугольник.

2023-08-04 Signal in Stochastic changed from bullish recovery to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.


Current temperature: 9.29
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 14.18
High with % probability:
Analyst Recommendations:
Number of estimates 1
Target Price Mean 19.00
Mean unverified/preliminary 19.00 / 19.00
Target Price Low / High 19.00 / 19.00
Median / STD DEV 19.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy None
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternNov. 20, 2024 After Top Gap Down - pattern is a made up of five candlesticks. Pattern appears on a uptrend. The pattern begins with a white candlestick. The next two days are also white days. The third day gaps up and opens above the close of the second day. The fifth day is a strong black with a gap below the previous day’s close. Considered to be a bearish reversal pattern.
ISIN US45781M1018
Website https://www.inva.com
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.